Saturday 17 October 2026
Export PROCF’s income statement to Excel — free account
Sofgen Pharma S.A
PROCF Healthcare Drug Manufacturers Specialty & Generic
0.03
0.00
0.00%
Follow PROCF
Sofgen Pharma S.A (PROCF) P/E ratio
As of 15 October 2026, Sofgen Pharma S.A (PROCF) trades at a P/E ratio of 0.1×. Over the past ten years it has ranged from 0.0× (October 2026) to 998× (March 2020); the current reading is higher than 47% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 19.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 5.8× | (45.33%) |
| FY2023 | 10.5× | (21.27%) |
| FY2022 | 13.4× | 15.67% |
| FY2022 | 11.6× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 985× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 10.5× | 34.92% |
| Sep 2023 | 7.8× | 8.91% |
| Jun 2023 | 7.2× | (58.71%) |
| Mar 2023 | 17.4× | 29.76% |
| 10 more quarters | Free account |
Against its own ten years
Low 0.0×
High 998×
Ten-year median
2.7×
Current reading's percentile
15
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CTOR Citius Oncology, Inc. compare | n/m |
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| PROCF Sofgen Pharma S.A | 0.1× |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 144× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)